Design, Development, and Evaluation of a Polyherbal Formulation for the Management of Metabolic Syndrome

Metabolic syndrome (MetS) represents a clustering of interconnected risk factors including central obesity, insulin resistance, dyslipidemia, and hypertension, which collectively increase the risk of type 2 diabetes mellitus and cardiovascular disease. The limitations of conventional single-target therapies in addressing this multifactorial condition have renewed interest in polyherbal formulations that can simultaneously target multiple pathological pathways. This study aimed to design, develop, and evaluate a polyherbal formulation combining extracts of Gymnema sylvestre, Camellia sinensis, Allium sativum, and Momordica charantia for the comprehensive management of metabolic syndrome. Individual plant extracts were prepared using appropriate extraction methods and subjected to phytochemical screening (qualitative and quantitative analysis by HPTLC). A polyherbal tablet formulation was developed using wet granulation technique and optimized through 3² factorial design with binder concentration (PVP K30) and disintegrant concentration (sodium starch glycolate) as independent variables, evaluating tablet hardness and disintegration time as responses. The optimized formulation was evaluated for in-vitro antioxidant activity (DPPH assay), enzyme inhibition potential (alpha-amylase and lipase inhibition assays), and glucose adsorption and diffusion retardation capacity. Phytochemical screening revealed abundant glycosides (4.82% gymnemic acid) in Gymnema sylvestre, high flavonoid content (12.67% epigallocatechin gallate) in Camellia sinensis, significant terpenoids in Allium sativum, and diverse phytoconstituents in Momordica charantia. Formulation optimization identified F5 (4% PVP K30, 4% sodium starch glycolate) as the optimal formulation with acceptable hardness (5.1 kg/cm²) and rapid disintegration time (6.2 minutes). The polyherbal formulation demonstrated potent antioxidant activity (IC₅₀ = 41.36 µg/mL; 81.75% inhibition at 100 µg/mL), significant alpha-amylase inhibition (IC₅₀ = 54.83 µg/mL; 74.92% inhibition at 200 µg/mL) with competitive inhibition kinetics, and moderate lipase inhibition (IC₅₀ = 72.58 µg/mL; 68.24% inhibition at 250 µg/mL). Glucose adsorption studies showed 15-17% glucose binding at physiologically relevant concentrations, while glucose diffusion was retarded by 32.39% during the critical initial absorption phase. The developed polyherbal formulation exhibits multi-mechanistic in-vitro bioactivity relevant to metabolic syndrome management, including antioxidant effects, enzyme inhibition (alpha-amylase and lipase), and glucose-modulating properties. The optimized formulation demonstrates acceptable pharmaceutical properties and provides a scientific rationale for further in-vivo evaluation. This multi-targeted approach aligns with the complex pathophysiology of metabolic syndrome and offers a promising complementary strategy to conventional therapies.

Hali tarjima qilinmagan